Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease

Hezzell, Melanie J; Boswood, Adrian; Chang, Yu‐Mei; Moonarmart, Walasinee; Elliott, Jonathan

doi:10.2460/ajvr.73.11.1765

Cited by 13 publications

(24 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Via its actions on the mineralocorticoid receptor, aldosterone promotes fluid retention, leading to volume-overload and stimulates myocardial fibrosis [12]. Urinary aldosterone to creatinine ratio (UAC) is associated with the rate of change of left ventricular size in dogs with MMVD, suggesting that aldosterone production increases during periods of active remodelling [13]. Spironolactone is a mineralocorticoid receptor antagonist that has been shown to prolong survival times in dogs with advanced MMVD and CHF secondary to MMVD, when given in combination with standard therapy [14].…”

Section: Introductionmentioning

confidence: 99%

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study

Hezzell

Boswood

López-Alvarez

et al. 2017

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study

Hezzell

Boswood

López-Alvarez

et al. 2017

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

“…We aimed to exclude other such disease processes by ensuring that thorough physical examinations and histories were performed and performing screening tests on HSDM cats when appropriate, including serum total T4 concentration and abdominal imaging (eg, ultrasound examinations or computed tomography), as well as by following the progress of cats after their initial visits. Two previous studies demonstrated use of PIIINP concentration in dogs . Future studies assessing the impact of common disease processes and varying physiological states in the cat also are indicated, but were beyond the scope of our current study.…”

Section: Discussionmentioning

confidence: 94%

“…Two previous studies demonstrated use of PIIINP concentration in dogs. 40,41 Future studies assessing the impact of common disease processes and varying physiological states in the cat also are indicated, but were beyond the scope of our current study. Using diabetic cats as a control group likely makes the findings of our study stronger, given the known high prevalence of comorbidities in diabetic cats, 42 all with potential to affect PIIINP concentrations.…”

Section: Discussionmentioning

confidence: 99%

Serum N‐Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism

Keyte

Kenny

Forcada

et al. 2016

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundN‐terminal type III procollagen propeptide (PIIINP) is a biomarker of soft tissue proliferation. Hypersomatotropism (HS) is associated with soft tissue proliferation.HypothesisSerum PIIINP is increased in cats with HS and decreases with effective treatment, and may be an additional tool in the diagnosis and treatment of feline HS.AnimalsCats with uncomplicated diabetes mellitus (DM; n = 30) and with HS‐induced DM (HSDM; n = 30). Pre‐ and posttreatment samples were available from 5 cats undergoing radiotherapy (RT) and 16 cats undergoing hypophysectomy (HPX).MethodsRetrospective and prospective cross‐sectional study. Analytical performance of a serum PIIINP ELISA was assessed and validated for use in cats. PIIINP and insulin‐like growth factor 1 (IGF‐1) radioimmunoassays (RIA) were performed pre‐ and post‐treatment in cats with DM and HSDM. PIIINP and IGF‐1 were compared between cats treated by RT and HPX.ResultsSerum PIIINP concentrations were significantly higher (P < .001) in HSDM cats (median, 19.6 ng/mL; range, 1.7–27.9) compared to DM cats (median, 5.0 ng/mL; range, 2.1–10.4). A cut‐off of 10.5 ng/mL allowed differentiation between DM and HSDM cats with 87% sensitivity and 100% specificity (area under the curve [AUC], 0.91; 95% confidence interval [CI], 0.82‐1). After RT, PIIINP increased significantly (P = .043) with no significant change in IGF‐1 concentrations. After HPX, serum PIIINP (P = .034) and IGF‐1 concentrations (P < .001) decreased significantly.Conclusion and clinical importance PIIINP concentrations are increased in cats with untreated HSDM compared to those with DM, demonstrating the effect of excess GH on soft tissue. PIIINP concentrations decreased after HPX in most HSDM cats.

show abstract

“…Although in‐house stability testing showed prolonged stability of serum aldosterone, sample degradation in plasma remains a possible cause of these low concentrations. Alternative explanations include the chronicity of benazepril treatment (16‐62 days, with median 33 days) and the possibility for reduced RAAS activation in the chronic, stable phase of CHF . Despite this, both treatments containing BNP1‐32 appeared to demonstrate an initial suppression and then a rise in aldosterone concentrations on visual inspection of Figure .…”

Section: Discussionmentioning

confidence: 99%

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease

Yata

Kooistra

Beijerink

2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background The effects of synthetic brain natriuretic peptide (BNP1‐32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown. Objectives To evaluate the cardiorenal and endocrine effects of SC administered synthetic canine BNP1‐32, with or without furosemide, in dogs with CHF caused by myxomatous mitral valve disease (MMVD). Animals Seven client‐owned male dogs with compensated American College of Veterinary Internal Medicine stage C CHF caused by MMVD on chronic treatment with furosemide, benazepril, and pimobendan. Methods A single‐dose, crossover, pilot study. Each dog received a dose of BNP1‐32 (5 μg/kg), furosemide (2 mg/kg), and both BNP1‐32/furosemide (5 μg/kg and 2 mg/kg, respectively) SC with a 2‐week washout period among each treatment. Between‐ and within‐treatment effects were evaluated using linear mixed modeling with restricted maximum likelihood estimation and evaluation of least square differences. Results Rapid absorption of BNP1‐32 and a corresponding rise in urinary cyclic guanosine monophosphate excretion was observed at 1‐2 hours after any treatment containing BNP1‐32 (P < .05). However, BNP1‐32 did not influence measured cardiorenal variables. Plasma aldosterone concentrations were below quantifiable levels in majority of the samples. Conclusions and Clinical Importance No beneficial cardiorenal effects were detected. It is possible that dogs with chronic CHF have a reduction in natriuretic peptide responsiveness.

show abstract

Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease

Abstract: In dogs with MMVD, echocardiographic indicators of left ventricular remodeling appeared to be associated with a decrease in serum concentration of a marker of collagen type III turnover and an increase in urinary aldosterone concentration.

Cited by 13 publications

References 46 publications

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study

Serum N‐Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism

Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease

Contact Info

Product

Resources

About